Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Rodman & Renshaw 18th Annual Global Investment Conference (September 2016)
33 slides from Prescient Therapeutics's conference presentation, Sep 13, 2016
Slide 1: Targeted therapies yielding a deep clinical pipeline
For personal use only Targeted therapies yielding a deep clinical pipeline » 3 clinical trials in oncology » First class team » All eyes on AML trial Prescient Therapeutics Limited (ASX: PTX) Rodman & Renshaw 18th Annual Global Investment Conference September 2016
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor For personal use only Certain statements made in this presentation are forward-looking statements within the meaning of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical fa
Slide 3: Company Overview
Company Overview For personal use only • 3 clinical trials in cancer: 2 underway and 1 on track to initiate One of Deepest Clinical imminently Pipelines on ASX • All under INDs Two Clinical Stage • 2 novel drug candidates targeting key cancer pathways Oncology Drugs » Akt (PTX-200) and Ras (PTX-100)
Slide 4: Investment Highlights
Investment Highlights For personal use only • One of deepest clinical pipelines on the ASX » Targeting hot areas of unmet clinical need • Targeted therapies with impeccable scientific pedigree • Funded through to value-accretive catalysts, with a fantastic share register • Phase 1b/2 AML trial is be
Slide 5: Deep, Clinical Stage Product Pipeline
Deep, Clinical Stage Product Pipeline For personal use only PTX has one of the deepest and most mature product pipelines on ASX Discovery Screening Preclinical Phase 1 Phase 1b Phase 2 Phase 3 PTX-200 Breast Cancer Finishing PTX-200 Ovarian Cancer Underway PTX-200 AML Imminent PTX-100 Solid tumors C
Slide 6: Corporate Snapshot
Corporate Snapshot For personal use only Key Metrics Share price performance ASX Ticker PTX Total Issued Capital 209.2 M shares Options 53.8 M Share Price1 A$0.105 Market Capitalisation1 A$22 M Cash Position2 A$9.7 M Shareholder Base Top 20 Own 52% 37 M shares; 6 month turnover1 A$3.9 M 36% Institut
Slide 7: Underpinned by extensive peer reviewed work
Underpinned by extensive peer reviewed work Science validated by >65 peer reviewed publications, including: For personal use only 7
Slide 8: PTX's valuation obviously doesn't weigh up!
PTX’s valuation obviously doesn’t weigh up! For personal use only Prestigious technology founders >$20 M Mechanism already of Action well invested 2 novel drugs understood targeting Akt and Ras/Rho All trials inhibition Highly under US experienced INDs team Clinically Phase 1b …and a current relevan
Slide 9: How Our Drugs Work: "Molecular Switches"
How Our Drugs Work: “Molecular Switches” For personal use only Akt & Ras are growth factors PTX’s drugs block the found in cancer cells – Akt & Ras growth signals, when they are turned on, switching the growth signals they send a signal to the off and causing the cancer cancer cell to grow cell to d
Slide 10: Akt is a Master Switch for Cellular Growth & Survival
Akt is a Master Switch for Cellular Growth & Survival For personal use only 10 Ersahin, T. et al; Mol. BioSyst., 2015,11, 1946-1954
Slide 11: Akt is an Important Drug Target
Akt is an Important Drug Target For personal use only • Akt pathway promotes cellular survival and growth PTX-00 (TCN-P) • Hyperactive Akt signaling has two deleterious effects: » Plays key role in the development of many cancers including breast, ovarian, colorectal, prostate, pancreatic and hemato
Slide 12: PTX-200: Novel Akt inhibition
PTX-200: Novel Akt inhibition For personal use only • A small molecule inhibitor of the Akt signaling pathway PTX-200 (TCN-P) • Inhibits Akt without the toxicity of other attempts • Anti-proliferative AND pro-apoptotic • Novel mechanism of action » NOT an ATP mimic; not a direct kinase inhibitor » I
Slide 13: In normal cells, Akt switches growth ON & OFF
In normal cells, Akt switches growth ON & OFF For personal use only Add Growth Factor Non-dividing Cell Dividing Cell Akt moves to cell membrane where it gets phosphorylated P Receptor Akt and activated to stimulate ON P cell division Akt is ON when phosphorylated and DNA Akt OFF OFF when not Synthe
Slide 14: When Akt is permanently switched ON, uncontrolled growth ensues
When Akt is permanently switched ON, uncontrolled growth (cancer) ensues For personal use only Untreated Cancer Cell Akt ON P Synthesis Uncontrolled Growth TUMOR Cell Division 14
Slide 15: PTX-200: Mechanism of Action – switching Akt OFF
PTX-200: Mechanism of Action – switching Akt OFF For personal use only Cancer Cells treated with PTX-200 Treatment With PTX-200 Akt ON P Akt OFF Prevents Akt from moving to membrane - keeping it in the OFF position Tumor Cells Stop Dividing 15
Slide 16: World Class Centers & Collaborations
World Class Centers & Collaborations For personal use only New York Connecticut Florida Previous clinical trials conducted at: 16
Slide 17: Working with the Moffitt Cancer Center
Working with the Moffitt Cancer Center For personal use only • H. Lee Moffitt Cancer Center & Research 1 2 Institute, established in 1986 in Tampa, Florida • 3rd largest cancer centre in the US • On one side of the campus is a world- leading “comprehensive cancer clinic” (1) » offering patients medi
Slide 18: Drugs don't develop themselves!
Drugs don’t develop themselves! • Proven success from discovery and clinical development through to FDA approvals. For personal use only • Professor and Chair, Department of Drug Discovery - Moffitt Cancer Center Said Sebti, PhD • Co-Program Leader, Chemical Biology and Molecular Medicine - Moffitt
Slide 19: Clinical Advocates Driving Our Programs
Clinical Advocates Driving Our Programs For personal use only Acute Myeloid Breast Cancer Ovarian Cancer Leukemia Jeff Lancet, M.D. Joseph Sparano, M.D. Heather Han, M.D. Robert Wenham, M.D. • Section Chief of • Prof. of Medicine & • Assistant Prof. of • Section Head, Leukemia in the Obstetrics, Gyn
Slide 20: World Class Scientific Advisory Board
World Class Scientific Advisory Board • Genuine international authorities, with particularly strong expertise in leukemia For personal use only • Professor of Oncologic Sciences, H. Lee Moffitt Cancer Center and University South Florida Jeff Lancet, • Section Chief of Leukemia in the Department of M
Slide 21: Acute Myeloid Leukemia Market Overview
Acute Myeloid Leukemia Market Overview For personal use only • AML is a type of cancer that affects the blood and bone marrow » Patient cannot produce normal blood cells » Blood cells cannot function properly nor fight disease • Progresses very quickly & 5 year survival is a dismal 25% • More common
Slide 22: Relevance of Akt in AML
Relevance of Akt in AML For personal use only • Frequent constitutive Akt activation (phosphorylation) in AML » Constitutive phosphorylation (Ser473 and Thr308) of Akt in AML compared to normal bone marrow cells in 44 out 66 of patients (72 %) • Implications for Akt as a modulator of chemotherapy re
Slide 23: PTX-200 synergizes cytarabine in AML cells
PTX-200 synergizes cytarabine in AML cells For personal use only • PTX-200 highly synergistic with cytarabine current standard of care in AML cells » PTX-200 + cytarabine = much more effective effect than the simple additive effect of either compound (i.e. 1 + 1 ≥ 2) • As cytarabine is the current s
Slide 24: PTX-200: Completed Phase 1 in AML (monotherapy)
PTX-200: Completed Phase 1 in AML (monotherapy) For personal use only Patients 32 Trial Centers MD Anderson & Moffitt Patient Advanced hematologic malignancies (mainly AML) Inclusion Administration 1 hour IV infusion on days 1, 8, and 15. Methods Cycles repeated every 21 days. Study To establish dos
Slide 25: PTX-200 reduced p-Akt in AML blasts
PTX-200 reduced p-Akt in AML blasts For personal use only • High p-AKT cells more sensitive to PTX-200 » p-Akt/Akt in AML » Action of PTX-200 on Akt samples before therapy phosphorylation in AML blasts 25 Lancet, et al. Leuk Res 2013; 37:1461
Slide 26: Compelling evidence for PTX-200 in AML
Compelling evidence for PTX-200 in AML For personal use only Efficacy hypothesis PTX-200 Evidence • High p-Akt is correlated with inferior survival in AML. • PTX-200 decreased pAkt in AML blasts. • Inhibiting p-Akt improves response to chemo in the • PTX-200 decreased pAkt in AML blasts, suggesting
Slide 27: Phase 1b Trial imminent: Acute Myeloid Leukemia
Phase 1b Trial imminent: Acute Myeloid Leukemia For personal use only . • PTX-200 plus cytarabine in refractory or relapsed AML • Phase 1 results very encouraging • Phase 1b/2 IND recently allowed by FDA • Jeff Lancet at Moffitt Cancer Center leading the trial Jeffrey E Lancet, M.D. Principal Invest
Slide 28: Breast Cancer Market Overview
Breast Cancer Market Overview • Breast cancer market currently US$10 B; due to double by 2023 For personal use only • Most breast cancer drug sales are for HER2+ cancers, but this only represents ̴20% of all breast cancers • By contrast, PTX is targeting “HER2 negative” (HER2-) breast cancer • HER2-
Slide 29: Phase 1b Breast Cancer Trial Almost Completed
Phase 1b Breast Cancer Trial Almost Completed For personal use only • PTX-200 in combination with paclitaxel, followed by doxorubicin and cyclophosphamide • Patients with metastatic and locally advanced breast cancer » Recruiting at Albert Einstein College of Medicine Montefiore Medical Center and t
Slide 30: Ovarian Cancer Market Overview
Ovarian Cancer Market Overview For personal use only • One of the most common cancers in women -increasing with an ageing population • Due to reach US$1.7 B by 2019 » Market size currently constrained by old generic drugs that just aren’t good enough • Standard of care has not changed in decades (of
Slide 31: Phase 1b Ovarian Cancer Trial Commenced
Phase 1b Ovarian Cancer Trial Commenced For personal use only • Significant need for new products to treat platinum-resistant ovarian cancer • Testing PTX-200 plus carboplatin in patients with platinum resistant ovarian cancer Robert Wenham, M.D. • PTX-200 already proven overcome cisplatin resistanc
Slide 32: Catalysts To Watch Out For
Catalysts To Watch Out For For personal use only 1H 2016 2H 2016 1H 2017 2H 2017 Phase Ib expansion Breast Complete Phase Ib cancer Phase 1b results Phase Ib dose escalation and interim Ovarian analysis cancer Complete Phase Ib IND allowed by US FDA Acute Initiate Phase Ib Myeloid Leukemia Dose es
Slide 33: Contact
For personal use only Contact Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics Limited E: steven@ptxtherapeutics.com M: +61 417 601 440 ptxtherapeutics.com